DUBLIN–(BUSINESS WIRE)–The “Global Fundus Cameras Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering. The analysts forecast the Global Fundus Cameras Market 2018-2022 to grow at a CAGR of 5.01% during the period 2018-2022. A…
Author: Business Wire
Illuma Names Healthcare and Business Veterans to Board, Aims to Link Thousands More At-Risk Diabetics with Proper Eye Care
ATLANTA–(BUSINESS WIRE)–In a year of major growth and milestones in its unique and innovative mission to prevent blindness for millions of at-risk diabetic patients nationwide, Illuma Care Connections has named a leading health plan executive and a v…
Aerie Pharmaceuticals to Announce Second Quarter 2018 Financial Results and Host Conference Call on Wednesday, August 8, 2018
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its second quarter 2018 financial results will be released after the market closes on Wednesday, August 8, 2018. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update. The live webcast and a replay may be accessed by visiting the Company’s website
Ophthotech Reports Second Quarter 2018 Financial and Operating Results
NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation today announced financial and operating results for the second quarter ended June 30, 2018 and provided a business update.
Aerie Pharmaceuticals, Inc. and DSM Biomedical, Inc. Expand Collaboration Agreement Focused on Novel Drug Delivery Technology in Ophthalmology
DURHAM, NC & EXTON, Pa.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, and DSM Biomedical, Inc., a global solutions provider in biomedical science and regenerative medicine, today reported that they have expanded their collaborative research, development, a
Ocular Therapeutix™ To Report Second Quarter 2018 Financial Results
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report second quarter ended June 30, 2018 financial results on Tuesday, August 7, 2018. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at
WILLIAMS-SONOMA, INC. DEMONSTRATES STRONG MOMENTUM IN COMMITMENT TO DELIVER VISION SERVICES TO OVER 20,000 FACTORY WORKERS
SAN FRANCISCO–(BUSINESS WIRE)–Williams-Sonoma, Inc. (NYSE: WSM) has partnered with VisionSpring, a non-profit organization with the mission of providing vision services and affordable eyewear, to help fund full vision services for at least 20,000 wor…
Thomas W. Burns, CEO of Glaukos, Joins Avedro’s Board of Directors
WALTHAM, Mass.–(BUSINESS WIRE)–#avedro–Avedro, Inc., an ophthalmic pharmaceutical and medical device company and the world leader in corneal remodeling, today announced that Thomas W. Burns has been elected to its Board of Directors. Mr. Burns has a…
Kala Pharmaceuticals Announces Dosing of First Patient in Phase 3 STRIDE 3 Trial of KPI-121 0.25% in Patients with Dry Eye Disease
WALTHAM, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced that the first patient has been dosed in STRIDE 3 (Short Term Relief In Dry Eye), its Phase 3 trial of KPI-121 0.25% for the short-term treatment of dry eye disease. “We are pleased to initiate the STRIDE 3 trial of KPI-121 0.25%. If approved, KPI-
Glaucoma Research Foundation Grant Leads to Major Breakthrough in Neuron Regeneration
SAN FRANCISCO–(BUSINESS WIRE)–#EyeCare–Research funded by the Glaucoma Research Foundation indicates use of insulin may lead to vision restoration in glaucoma patients.
Global Ocular Inflammation Ongoing Clinical Trials – Analysis & Outlook to 2022 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ocular Inflammation Ongoing Global Clinical Trials Analysis and Outlook” report has been added to ResearchAndMarkets.com’s offering.Ocular Inflammation ongoing clinical trials report provides comprehensive analysis and tre…
Global Ocular Melanoma Ongoing Clinical Trials – Analysis & Outlook to 2022 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ocular Melanoma Ongoing Global Clinical Trials Analysis and Outlook” report has been added to ResearchAndMarkets.com’s offering. Ocular Melanoma ongoing clinical trials report provides comprehensive analysis and trends in …
NovaBay Pharmaceuticals to Hold Second Quarter 2018 Conference Call on August 7, 2018
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay Pharmaceuticals to Hold Second Quarter 2018 Conference Call on August 7, 2018
Global Rhino-Conjunctivitis Ongoing Clinical Trials – Analysis & Outlook to 2022 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Rhino-Conjunctivitis Ongoing Global Clinical Trials Analysis and Outlook” report has been added to ResearchAndMarkets.com’s offering. Rhino-Conjunctivitis ongoing clinical trials report provides comprehensive analysis and …
RadianceTx Raises $1 Million First Tranche to Develop Novel Glaucoma Therapy
TUCSON, Ariz. & LONDON–(BUSINESS WIRE)–RadianceTx™, a leader in ophthalmic therapeutic innovation, today announced a $1 million first tranche closing of a targeted $7 million round of financing. The investment will be used to fund development of the Company’s Beta Ophthalmic System for delivery of beta irradiation therapy to improve glaucoma surgery outcomes. Validated in three clinical studies conducted by preeminent ophthalmic research teams, beta therapy has been shown to improve glaucoma
Neuromyelitis Optica (Devic’s Syndrome) | A Drug Pipeline Analysis Report 2018 | Technavio
LONDON–(BUSINESS WIRE)–#Devicssyndrome–Technavio has published a new report on the drug development pipeline for neuromyelitis optica (Devic’s syndrome).
SeniorWell Expands Service to Ohio and Wisconsin
CHICAGO–(BUSINESS WIRE)–SeniorWell, a mobile healthcare company, today announced its expansion into Ohio and Wisconsin.
Ophthotech Corporation to Report Second Quarter 2018 Financial Results and Host Conference Call on Wednesday, August 1, 2018
NEW YORK–(BUSINESS WIRE)–Ophthotech announced that it will report its second quarter 2018 financial and operating results on Wed., Aug. 1, 2018.
Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive, top line results from the Phase II LADDER study evaluating the efficacy and safety of its investigational Port …
Data from BioTime’s OpRegen® Program to Be Presented at AAO 2018
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its abstract “PI/IIa Study of Subretinally Transplanted Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry-Form AMD Patients,” has been accepted for an oral presentation at the upcoming American Academy of Ophthalmology (AAO) meeting taking place from October 27th – October 30th, 2018, in Chicago, Illinois. “We are delighted